Why a few kids are still dying from childhood leukemia

Children are still being diagnosed with leukemia and other childhood cancers.

But in some cases, parents are being told they have to wait years or even decades before seeing their child.

The latest news on childhood leukemia is in the AP’s “Child and Adolescent Health” section.

It was written by AP science and technology reporter Scott Belsky and features a story on a new drug, known as CARV, that’s been shown to slow the progression of the disease.

A new drug that slows the progression and death of leukemia could help prevent thousands of children and teens from dying from the disease, according to a study published Monday.

Researchers say the drug could also make it easier for parents to see their children.CARV, also known as Zv2, is a protein made by a bacterium called E. coli.

CARV has been shown in laboratory studies to slow down the growth of certain cancers.

CARVs main side effect is inflammation of the blood vessels in the brain, spinal cord and other areas.

A study published in March by researchers at Duke University and the National Institutes of Health showed that CARV was more effective at slowing the growth and death rates of leukemia and its most aggressive forms than the standard treatments that people take to control the disease and its symptoms.

In their study, researchers used mice that had leukemia, and then tested the mice’ blood and cells in laboratory dishes.

The researchers found that the CARVs proteins blocked the growth or death of several leukemia cells.CARVs drugs, like Zv1, had a similar effect.CARVEll, made by GSK, the Swiss drug maker, is made by AstraZeneca.

The new drug has been tested in animal studies, and has been approved for use in humans.

The scientists say the drugs could be made available to parents of children with leukemia, but the government hasn’t made a decision on whether or not to approve it.

The AP’s story on the study is in its “Child Health” tab.

Follow AP health and science reporter Jill Disis on Twitter at: @jdisisAP.